サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1179557

がん幹細胞市場：がんの形態別、用途別：世界の機会分析および産業予測、2021-2031年

Cancer Stem Cells Market By Cancer Forms, By Application : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 200 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円
がん幹細胞市場：がんの形態別、用途別：世界の機会分析および産業予測、2021-2031年
出版日: 2022年09月01日
発行: Allied Market Research
ページ情報: 英文 200 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがん幹細胞市場は、2021年の10億5520万米ドルから、2022年から2031年にかけてCAGR10.0％で成長し、2031年までに27億1180万米ドルを獲得すると想定されています。

がんは、人間の生命に大きな脅威を与える時間的な病です。がんの治療には、手術、化学療法、放射線療法、標的治療など、さまざまな方法が開発されています。これらの治療法のおかげで、がんの罹患率は女性で安定し、男性ではやや減少し、がんによる死亡率も同じ期間で減少しています。従来のがん治療では、特定の悪性腫瘍にしか効かないこと、転移、不均一性、さらに化学療法や放射線療法への耐性、免疫監視の回避などが、がん治療失敗の主な原因となっています。これらの失敗の原因は、がん幹細胞の特徴にあると考えられます。がん幹細胞は、初期に停止して新たな腫瘍を形成する性質があるため、がんの広がりや再発、多剤耐性、放射線耐性などを引き起こす可能性があります。そのため、がん幹細胞は、がんの有効な治療法として最も有望視されています。

幹細胞移植は、悪性腫瘍の診断に用いられる放射線治療など、臨床的な処置が複雑でリスクが高いです。がん幹細胞（CSC）と通常の幹細胞は、多くの基本的な生物学的シグナル伝達経路を共有しています。正常な幹細胞は、その微小環境がネガティブに変化したときにCSCとなり、完全な腫瘍組織が作られる可能性があります。移植された幹細胞は、移植前の培養中に、ゲノム発現や将来の表現型を変化させる可能性のある環境因子にさらされる可能性があります。幹細胞は、培養時間が長くなるとがん細胞になる可能性が高くなります。これらの要因は、予測期間中のがん幹細胞市場の成長を妨げると予測されます。

がん幹細胞は、がん細胞の再発や転移の原因の一つです。また、がん幹細胞は、化学療法の大部分に対して耐性があります。さらに、がん幹細胞は、腫瘍細胞の不均一性や再発にある程度寄与しています。腫瘍の完全な退縮を達成するためには、がん幹細胞に対処する必要があります。最近の免疫療法の発展は、がん治療において有望な結果を示しており、それはがん幹細胞にも適用可能です。異なる腫瘍に存在するがん幹細胞は、免疫学的マーカーを発現し、特定の免疫特性を示します。この特性を利用して、腫瘍の微小環境にあるがん幹細胞を標的とした免疫療法を行うことができるのです。がん幹細胞は、近年、技術的な進歩や研究開発において大きな注目を集めています。がん幹細胞は、樹状細胞（DC）ベースのワクチン、適応型T細胞、オンコリティックウイルス、免疫チェックポイント阻害剤、および併用療法を用いてますます標的とされるようになってきています。

COVID-19のパンデミックは、世界中のさまざまなビジネスが停止し、深刻な経済的損失につながるいくつかの不確実性をもたらしました。COVID-19の発生は、がん幹細胞市場の成長に大きな影響を及ぼしました。世界のがん患者の増加により、有効ながん幹細胞治療へのニーズが高まっています。がん幹細胞の研究者は、様々な政府機関とともに、COVID-19の大流行時のがん細胞治療の需要増に対応するために、細胞ベースの治療法の研究開発活動に大規模な投資を行っています。例えば、COVID-19パンデミックの間、COVID-19パンデミックに対する抵抗力のための幹細胞の適用性が研究されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19 影響分析
  • 規制ガイドライン
  • バリューチェーン分析
  • 市場シェア分析
  • 主要規制の分析
  • 特許情勢

第4章 がん幹細胞市場：がんの形態別

  • 概要
    • 市場規模および予測
  • 乳房
    • 主な市場動向、成長要因、機会
    • 市場規模および予測：地域別
    • 市場分析：国別
  • 血液
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 肺
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 脳
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 大腸
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 膵臓
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 膀胱
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 肝臓
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第5章 がん幹細胞市場：応用分野別

  • 概要
    • 市場規模および予測
  • 開発されたがん幹細胞
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 幹細胞別がん治療
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第6章 がん幹細胞市場：地域別

  • 概要
    • 市場規模および予測
  • 北米
    • 主要動向と機会
    • 北米市場規模・予測：がん腫型別
    • 北米市場規模・予測：用途別
    • 北米市場規模・予測：国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主要動向と機会
    • 欧州市場規模・予測：がんの形態別
    • 欧州市場規模・予測：用途別
    • 欧州市場規模・予測：国別
      • ドイツ
      • 英国
      • フランス
      • スペイン
      • イタリア
      • その他の欧州地域
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模・予測：がんの形態別
    • アジア太平洋地域の市場規模・予測：用途別
    • アジア太平洋地域の市場規模・予測：国別
      • 中国
      • 日本
      • インド
      • 韓国
      • オーストラリア
      • その他アジア太平洋地域
  • LAMEA
    • 主要動向と機会
    • LAMEAの市場規模・予測：がんの形態別
    • LAMEAの市場規模・予測：用途別
    • LAMEAの市場規模・予測：国別
      • ブラジル
      • サウジアラビア
      • UAE
      • 南アフリカ
      • LAMEAの残りの地域

第7章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主な発展

第8章 企業プロファイル

  • Thermo Fisher Scientific Inc.
  • AbbVie Inc.
  • Miltenyi Biotec
  • STEMCELL Technologies Inc.
  • Merck KGaA
  • Stemline Therapeutics, Inc.
  • MacroGenics, Inc.
  • Bionomics
  • FUJIFILM Irvine Scientific.
  • Lineage Cell Therapeutics, Inc.
図表

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 2. CANCER STEM CELLS MARKET SIZE, FOR BREAST, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. CANCER STEM CELLS MARKET FOR BREAST, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. CANCER STEM CELLS MARKET SIZE, FOR BLOOD, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. CANCER STEM CELLS MARKET FOR BLOOD, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. CANCER STEM CELLS MARKET SIZE, FOR LUNG, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. CANCER STEM CELLS MARKET FOR LUNG, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. CANCER STEM CELLS MARKET SIZE, FOR BRAIN, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. CANCER STEM CELLS MARKET FOR BRAIN, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 10. CANCER STEM CELLS MARKET SIZE, FOR COLORECTAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. CANCER STEM CELLS MARKET FOR COLORECTAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 12. CANCER STEM CELLS MARKET SIZE, FOR PANCREATIC, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. CANCER STEM CELLS MARKET FOR PANCREATIC, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 14. CANCER STEM CELLS MARKET SIZE, FOR BLADDER, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. CANCER STEM CELLS MARKET FOR BLADDER, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 16. CANCER STEM CELLS MARKET SIZE, FOR LIVER, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. CANCER STEM CELLS MARKET FOR LIVER, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 18. CANCER STEM CELLS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 19. CANCER STEM CELLS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 20. GLOBAL CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 21. CANCER STEM CELLS MARKET SIZE, FOR TRAGETED CANCEROUS STEM CELLS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 22. CANCER STEM CELLS MARKET FOR TRAGETED CANCEROUS STEM CELLS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 23. CANCER STEM CELLS MARKET SIZE, FOR STEM CELL-BASED CANCER THERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 24. CANCER STEM CELLS MARKET FOR STEM CELL-BASED CANCER THERAPY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 25. CANCER STEM CELLS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 26. NORTH AMERICA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 27. NORTH AMERICA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 28. NORTH AMERICA CANCER STEM CELLS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 29. U.S. CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 30. U.S. CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 31. CANADA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 32. CANADA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 33. MEXICO CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 34. MEXICO CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 35. EUROPE CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 36. EUROPE CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 37. EUROPE CANCER STEM CELLS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 38. GERMANY CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 39. GERMANY CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 40. UNITED KINGDOM CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 41. UNITED KINGDOM CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 42. FRANCE CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 43. FRANCE CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 44. SPAIN CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 45. SPAIN CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 46. ITALY CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 47. ITALY CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 48. REST OF EUROPE CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 49. REST OF EUROPE CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 50. ASIA-PACIFIC CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 51. ASIA-PACIFIC CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 52. ASIA-PACIFIC CANCER STEM CELLS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 53. CHINA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 54. CHINA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 55. JAPAN CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 56. JAPAN CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 57. INDIA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 58. INDIA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 59. SOUTH KOREA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 60. SOUTH KOREA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 61. AUSTRALIA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 62. AUSTRALIA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 63. REST OF ASIA PACIFIC CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 64. REST OF ASIA PACIFIC CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 65. LAMEA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 66. LAMEA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 67. LAMEA CANCER STEM CELLS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 68. BRAZIL CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 69. BRAZIL CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 70. SAUDI ARABIA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 71. SAUDI ARABIA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 72. UAE CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 73. UAE CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 74. SOUTH AFRICA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 75. SOUTH AFRICA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 76. REST OF LAMEA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 77. REST OF LAMEA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 78.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 79.THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 80.THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 81.THERMO FISHER SCIENTIFIC INC.: NET SALES,
  • TABLE 82.THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
  • TABLE 83.ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 84.ABBVIE INC.: OPERATING SEGMENTS
  • TABLE 85.ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 86.ABBVIE INC.: NET SALES,
  • TABLE 87.ABBVIE INC.: KEY STRATERGIES
  • TABLE 88.MILTENYI BIOTEC: COMPANY SNAPSHOT
  • TABLE 89.MILTENYI BIOTEC: OPERATING SEGMENTS
  • TABLE 90.MILTENYI BIOTEC: PRODUCT PORTFOLIO
  • TABLE 91.MILTENYI BIOTEC: NET SALES,
  • TABLE 92.MILTENYI BIOTEC: KEY STRATERGIES
  • TABLE 93.STEMCELL TECHNOLOGIES INC.: COMPANY SNAPSHOT
  • TABLE 94.STEMCELL TECHNOLOGIES INC.: OPERATING SEGMENTS
  • TABLE 95.STEMCELL TECHNOLOGIES INC.: PRODUCT PORTFOLIO
  • TABLE 96.STEMCELL TECHNOLOGIES INC.: NET SALES,
  • TABLE 97.STEMCELL TECHNOLOGIES INC.: KEY STRATERGIES
  • TABLE 98.MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 99.MERCK KGAA: OPERATING SEGMENTS
  • TABLE 100.MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 101.MERCK KGAA: NET SALES,
  • TABLE 102.MERCK KGAA: KEY STRATERGIES
  • TABLE 103.STEMLINE THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 104.STEMLINE THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 105.STEMLINE THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 106.STEMLINE THERAPEUTICS, INC.: NET SALES,
  • TABLE 107.STEMLINE THERAPEUTICS, INC.: KEY STRATERGIES
  • TABLE 108.MACROGENICS, INC.: COMPANY SNAPSHOT
  • TABLE 109.MACROGENICS, INC.: OPERATING SEGMENTS
  • TABLE 110.MACROGENICS, INC.: PRODUCT PORTFOLIO
  • TABLE 111.MACROGENICS, INC.: NET SALES,
  • TABLE 112.MACROGENICS, INC.: KEY STRATERGIES
  • TABLE 113.BIONOMICS: COMPANY SNAPSHOT
  • TABLE 114.BIONOMICS: OPERATING SEGMENTS
  • TABLE 115.BIONOMICS: PRODUCT PORTFOLIO
  • TABLE 116.BIONOMICS: NET SALES,
  • TABLE 117.BIONOMICS: KEY STRATERGIES
  • TABLE 118.FUJIFILM IRVINE SCIENTIFIC.: COMPANY SNAPSHOT
  • TABLE 119.FUJIFILM IRVINE SCIENTIFIC.: OPERATING SEGMENTS
  • TABLE 120.FUJIFILM IRVINE SCIENTIFIC.: PRODUCT PORTFOLIO
  • TABLE 121.FUJIFILM IRVINE SCIENTIFIC.: NET SALES,
  • TABLE 122.FUJIFILM IRVINE SCIENTIFIC.: KEY STRATERGIES
  • TABLE 123.LINEAGE CELL THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 124.LINEAGE CELL THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 125.LINEAGE CELL THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 126.LINEAGE CELL THERAPEUTICS, INC.: NET SALES,
  • TABLE 127.LINEAGE CELL THERAPEUTICS, INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.CANCER STEM CELLS MARKET SEGMENTATION
  • FIGURE 2.CANCER STEM CELLS MARKET,2021-2031
  • FIGURE 3.CANCER STEM CELLS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.CANCER STEM CELLS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.REGULATORY GUIDELINES
  • FIGURE 13.VALUE CHAIN ANALYSIS
  • FIGURE 14.MARKET SHARE ANALYSIS
  • FIGURE 15.KEY REGULATION ANALYSIS
  • FIGURE 16.PATENT ANALYSIS BY COMPANY
  • FIGURE 17.PATENT ANALYSIS BY COUNTRY
  • FIGURE 18.CANCER STEM CELLS MARKET,BY CANCER FORMS,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF BREAST CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF BLOOD CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF LUNG CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF BRAIN CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF COLORECTAL CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF PANCREATIC CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF BLADDER CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF LIVER CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 27.COMPARATIVE SHARE ANALYSIS OF OTHERS CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 28.CANCER STEM CELLS MARKET,BY APPLICATION,2021(%)
  • FIGURE 29.COMPARATIVE SHARE ANALYSIS OF TRAGETED CANCEROUS STEM CELLS CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 30.COMPARATIVE SHARE ANALYSIS OF STEM CELL-BASED CANCER THERAPY CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 31.CANCER STEM CELLS MARKET BY REGION,2021
  • FIGURE 32.U.S. CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 33.CANADA CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 34.MEXICO CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 35.GERMANY CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 36.UNITED KINGDOM CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 37.FRANCE CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 38.SPAIN CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 39.ITALY CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 40.REST OF EUROPE CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 41.CHINA CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 42.JAPAN CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 43.INDIA CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 44.SOUTH KOREA CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 45.AUSTRALIA CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 46.REST OF ASIA PACIFIC CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 47.BRAZIL CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 48.SAUDI ARABIA CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 49.UAE CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 50.SOUTH AFRICA CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 51.REST OF LAMEA CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 52. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 53. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 54. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 55.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 56.COMPETITIVE DASHBOARD
  • FIGURE 57.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 58.THERMO FISHER SCIENTIFIC INC..: NET SALES ,($MILLION)
  • FIGURE 59.ABBVIE INC..: NET SALES ,($MILLION)
  • FIGURE 60.MILTENYI BIOTEC.: NET SALES ,($MILLION)
  • FIGURE 61.STEMCELL TECHNOLOGIES INC..: NET SALES ,($MILLION)
  • FIGURE 62.MERCK KGAA.: NET SALES ,($MILLION)
  • FIGURE 63.STEMLINE THERAPEUTICS, INC..: NET SALES ,($MILLION)
  • FIGURE 64.MACROGENICS, INC..: NET SALES ,($MILLION)
  • FIGURE 65.BIONOMICS.: NET SALES ,($MILLION)
  • FIGURE 66.FUJIFILM IRVINE SCIENTIFIC..: NET SALES ,($MILLION)
  • FIGURE 67.LINEAGE CELL THERAPEUTICS, INC..: NET SALES ,($MILLION)
目次
Product Code: A08105

The global cancer stem cells market is envisioned to garner $2,711.8 million by 2031, growing from $1,055.2 million in 2021 at a CAGR of 10.0% from 2022 to 2031.

Cancers are time-related illnesses that pose a major threat to human life. For the treatment of cancer, a variety of methods have been developed, including surgery, chemo, radiation, and targeted therapy. Because of all these treatments, the incidence rate of cancer has been steady in women and has somewhat decreased in males, and the death rate from cancer has also decreased over the same period. Traditional cancer treatments, which only work for certain types of malignant tumors, metastasis, heterogeneity, as well as resistance to chemotherapy, radiotherapy, and avoiding immunological surveillance are the primary causes of cancer treatment failures. The traits of cancer stem cells could be the cause of all these failures. Due to their capacity to stop in the early phase, which results in the formation of fresh tumors, cancer stem cells can lead to cancer spread, cancer relapse, multidrug resistance, and radiation resistance. Cancer stem cells may therefore be considered of as the most promising cancer effective treatments.

The clinical procedures involved in stem cell transplantation are complex and high risk, including radiation therapy that is used to diagnose malignancy. Cancer stem cells (CSCs) and regular stem cells share many fundamental biologicals signaling pathways. Normal stem cells may become CSCs when their microenvironment changes negatively, which then causes the creation of the complete tumor tissue. While in culture prior to transplantation, transplanted stem cells may be exposed to environmental factors that could alter their genomic expression and future phenotype. Stem cells are more likely to become cancerous cells with increased culture time. These factors are predicted to hamper the cancer stem cells market growth in forecast time period.

Cancer stem cells are one of the causes of cancer cell relapse and metastasis. They are resistant to the majority of chemotherapeutic treatments. Additionally, cancer stem cell contributes to tumor cell heterogeneity and recurrent illness to some extent. Cancer stem cells must be addressed if total tumor regression is to be achieved. Recent developments in immunotherapies have demonstrated encouraging results in the treatment of cancer, which are also applicable to cancer stem cells. Cancer stem cells in different tumors express immunological markers and show certain immune traits, which can be exploited in immunotherapies to target cancer stem cells in the tumor microenvironment. Cancer stem cells have recently gained huge traction when it comes to technological advancements as well as research & development (R&D) initiatives. Cancer stem cells are increasingly being targeted using dendritic cell (DC)-based vaccines, adaptive T-cells, oncolytic viruses, immune checkpoint inhibitors, and combination treatments.

The COVID-19 pandemic brought several uncertainties leading to severe economic losses as various businesses across the world were at a standstill. The COVID-19 outbreak caused a significant effect on the cancer stem cell market growth. The rise in cancer cases globally is increasing the need for efficacious cancer stem cell therapies. Cancer stem cell researchers along with various government bodies are massively investing in Research and Development activities for cell-based therapies to cater to the rising demand for cancer cell therapies during the COVID-19 pandemic. For instance, during the COVID-19 pandemic, the use of stem cell applicability for resistance to the COVID-19 pandemic is researched.

The key players profiled in this report include: AdnaGen GmbH, Advanced Cell Diagnostics, Inc., AVIVA Biosciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc. and Silicon Biosystems, S.p.A.

Key Market Segments

By Cancer Forms

  • Breast
  • Blood
  • Lung
  • Brain
  • Colorectal
  • Pancreatic
  • Bladder
  • Liver
  • Others

By Application

  • Trageted Cancerous Stem Cells
  • Stem Cell-based cancer Therapy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest Of Asia Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Thermo Fisher Scientific Inc.
    • AbbVie Inc.
    • Miltenyi Biotec
    • STEMCELL Technologies Inc.
    • Merck KGaA
    • Stemline Therapeutics, Inc.
    • MacroGenics, Inc.
    • Bionomics
    • FUJIFILM Irvine Scientific.
    • Lineage Cell Therapeutics, Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Regulatory Guidelines
  • 3.8.Value Chain Analysis
  • 3.9.Market Share Analysis
  • 3.10.Key Regulation Analysis
  • 3.11.Patent Landscape

CHAPTER 4: CANCER STEM CELLS MARKET, BY CANCER FORMS

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Breast
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Blood
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Lung
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 Brain
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country
  • 4.6 Colorectal
    • 4.6.1 Key market trends, growth factors and opportunities
    • 4.6.2 Market size and forecast, by region
    • 4.6.3 Market analysis by country
  • 4.7 Pancreatic
    • 4.7.1 Key market trends, growth factors and opportunities
    • 4.7.2 Market size and forecast, by region
    • 4.7.3 Market analysis by country
  • 4.8 Bladder
    • 4.8.1 Key market trends, growth factors and opportunities
    • 4.8.2 Market size and forecast, by region
    • 4.8.3 Market analysis by country
  • 4.9 Liver
    • 4.9.1 Key market trends, growth factors and opportunities
    • 4.9.2 Market size and forecast, by region
    • 4.9.3 Market analysis by country
  • 5.0 Others
    • 5.0.1 Key market trends, growth factors and opportunities
    • 5.0.2 Market size and forecast, by region
    • 5.0.3 Market analysis by country

CHAPTER 5: CANCER STEM CELLS MARKET, BY APPLICATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Trageted Cancerous Stem Cells
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Stem Cell-based cancer Therapy
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country

CHAPTER 6: CANCER STEM CELLS MARKET, BY REGION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 North America
    • 6.2.1 Key trends and opportunities
    • 6.2.2 North America Market size and forecast, by Cancer Forms
    • 6.2.3 North America Market size and forecast, by Application
    • 6.2.4 North America Market size and forecast, by country
      • 6.2.4.1 U.S.
      • 6.2.4.1.1 Market size and forecast, by Cancer Forms
      • 6.2.4.1.2 Market size and forecast, by Application
      • 6.2.4.2 Canada
      • 6.2.4.2.1 Market size and forecast, by Cancer Forms
      • 6.2.4.2.2 Market size and forecast, by Application
      • 6.2.4.3 Mexico
      • 6.2.4.3.1 Market size and forecast, by Cancer Forms
      • 6.2.4.3.2 Market size and forecast, by Application
  • 6.3 Europe
    • 6.3.1 Key trends and opportunities
    • 6.3.2 Europe Market size and forecast, by Cancer Forms
    • 6.3.3 Europe Market size and forecast, by Application
    • 6.3.4 Europe Market size and forecast, by country
      • 6.3.4.1 Germany
      • 6.3.4.1.1 Market size and forecast, by Cancer Forms
      • 6.3.4.1.2 Market size and forecast, by Application
      • 6.3.4.2 United Kingdom
      • 6.3.4.2.1 Market size and forecast, by Cancer Forms
      • 6.3.4.2.2 Market size and forecast, by Application
      • 6.3.4.3 France
      • 6.3.4.3.1 Market size and forecast, by Cancer Forms
      • 6.3.4.3.2 Market size and forecast, by Application
      • 6.3.4.4 Spain
      • 6.3.4.4.1 Market size and forecast, by Cancer Forms
      • 6.3.4.4.2 Market size and forecast, by Application
      • 6.3.4.5 Italy
      • 6.3.4.5.1 Market size and forecast, by Cancer Forms
      • 6.3.4.5.2 Market size and forecast, by Application
      • 6.3.4.6 Rest of Europe
      • 6.3.4.6.1 Market size and forecast, by Cancer Forms
      • 6.3.4.6.2 Market size and forecast, by Application
  • 6.4 Asia-Pacific
    • 6.4.1 Key trends and opportunities
    • 6.4.2 Asia-Pacific Market size and forecast, by Cancer Forms
    • 6.4.3 Asia-Pacific Market size and forecast, by Application
    • 6.4.4 Asia-Pacific Market size and forecast, by country
      • 6.4.4.1 China
      • 6.4.4.1.1 Market size and forecast, by Cancer Forms
      • 6.4.4.1.2 Market size and forecast, by Application
      • 6.4.4.2 Japan
      • 6.4.4.2.1 Market size and forecast, by Cancer Forms
      • 6.4.4.2.2 Market size and forecast, by Application
      • 6.4.4.3 India
      • 6.4.4.3.1 Market size and forecast, by Cancer Forms
      • 6.4.4.3.2 Market size and forecast, by Application
      • 6.4.4.4 South Korea
      • 6.4.4.4.1 Market size and forecast, by Cancer Forms
      • 6.4.4.4.2 Market size and forecast, by Application
      • 6.4.4.5 Australia
      • 6.4.4.5.1 Market size and forecast, by Cancer Forms
      • 6.4.4.5.2 Market size and forecast, by Application
      • 6.4.4.6 Rest Of Asia Pacific
      • 6.4.4.6.1 Market size and forecast, by Cancer Forms
      • 6.4.4.6.2 Market size and forecast, by Application
  • 6.5 LAMEA
    • 6.5.1 Key trends and opportunities
    • 6.5.2 LAMEA Market size and forecast, by Cancer Forms
    • 6.5.3 LAMEA Market size and forecast, by Application
    • 6.5.4 LAMEA Market size and forecast, by country
      • 6.5.4.1 Brazil
      • 6.5.4.1.1 Market size and forecast, by Cancer Forms
      • 6.5.4.1.2 Market size and forecast, by Application
      • 6.5.4.2 Saudi Arabia
      • 6.5.4.2.1 Market size and forecast, by Cancer Forms
      • 6.5.4.2.2 Market size and forecast, by Application
      • 6.5.4.3 UAE
      • 6.5.4.3.1 Market size and forecast, by Cancer Forms
      • 6.5.4.3.2 Market size and forecast, by Application
      • 6.5.4.4 South Africa
      • 6.5.4.4.1 Market size and forecast, by Cancer Forms
      • 6.5.4.4.2 Market size and forecast, by Application
      • 6.5.4.5 Rest of LAMEA
      • 6.5.4.5.1 Market size and forecast, by Cancer Forms
      • 6.5.4.5.2 Market size and forecast, by Application

CHAPTER 7: COMPANY LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Key developments

CHAPTER 8: COMPANY PROFILES

  • 8.1 Thermo Fisher Scientific Inc.
    • 8.1.1 Company overview
    • 8.1.2 Company snapshot
    • 8.1.3 Operating business segments
    • 8.1.4 Product portfolio
    • 8.1.5 Business performance
    • 8.1.6 Key strategic moves and developments
  • 8.2 AbbVie Inc.
    • 8.2.1 Company overview
    • 8.2.2 Company snapshot
    • 8.2.3 Operating business segments
    • 8.2.4 Product portfolio
    • 8.2.5 Business performance
    • 8.2.6 Key strategic moves and developments
  • 8.3 Miltenyi Biotec
    • 8.3.1 Company overview
    • 8.3.2 Company snapshot
    • 8.3.3 Operating business segments
    • 8.3.4 Product portfolio
    • 8.3.5 Business performance
    • 8.3.6 Key strategic moves and developments
  • 8.4 STEMCELL Technologies Inc.
    • 8.4.1 Company overview
    • 8.4.2 Company snapshot
    • 8.4.3 Operating business segments
    • 8.4.4 Product portfolio
    • 8.4.5 Business performance
    • 8.4.6 Key strategic moves and developments
  • 8.5 Merck KGaA
    • 8.5.1 Company overview
    • 8.5.2 Company snapshot
    • 8.5.3 Operating business segments
    • 8.5.4 Product portfolio
    • 8.5.5 Business performance
    • 8.5.6 Key strategic moves and developments
  • 8.6 Stemline Therapeutics, Inc.
    • 8.6.1 Company overview
    • 8.6.2 Company snapshot
    • 8.6.3 Operating business segments
    • 8.6.4 Product portfolio
    • 8.6.5 Business performance
    • 8.6.6 Key strategic moves and developments
  • 8.7 MacroGenics, Inc.
    • 8.7.1 Company overview
    • 8.7.2 Company snapshot
    • 8.7.3 Operating business segments
    • 8.7.4 Product portfolio
    • 8.7.5 Business performance
    • 8.7.6 Key strategic moves and developments
  • 8.8 Bionomics
    • 8.8.1 Company overview
    • 8.8.2 Company snapshot
    • 8.8.3 Operating business segments
    • 8.8.4 Product portfolio
    • 8.8.5 Business performance
    • 8.8.6 Key strategic moves and developments
  • 8.9 FUJIFILM Irvine Scientific.
    • 8.9.1 Company overview
    • 8.9.2 Company snapshot
    • 8.9.3 Operating business segments
    • 8.9.4 Product portfolio
    • 8.9.5 Business performance
    • 8.9.6 Key strategic moves and developments
  • 8.10 Lineage Cell Therapeutics, Inc.
    • 8.10.1 Company overview
    • 8.10.2 Company snapshot
    • 8.10.3 Operating business segments
    • 8.10.4 Product portfolio
    • 8.10.5 Business performance
    • 8.10.6 Key strategic moves and developments